Prostate cancer is a severe health problem worldwide, and timely and accurate diagnosis is essential for effective treatment planning. In recent years, multiparametric magnetic resonance imaging (mpMRI) has emerged as a powerful noninvasive tool in detecting and characterizing prostate cancer. The clinical application of mpMRI has changed the diagnostic landscape, allowing for improved risk stratification and guided targeted biopsies. Professor Chang Wook Jeong [1] contributed a review article that provides a comprehensive analysis of the use of magnetic resonance imaging (MRI) and fusion biopsy in the context of active surveillance for prostate cancer. Professor Byung Kwan Park [2] drew on his extensive experience to point out the limitations of the current PI-RADS (Prostate Imaging and Reporting and Data System) version 2.1. Professors Jun Nyung Lee and Tae Gyun Kwon [3] authored an original paper presenting an innovative study on the importance of multivariate MRI in predicting extraprostatic extension in prostate cancer patients. Finally, Professor Kyung Kgi Park [4] offers a cost-benefit comparison of biparametric MRI in a study highlighting the economic implications of using this imaging modality in evaluating prostate cancer.

Modern genetic testing is critical for identifying genetic risk factors, prognostic markers, and therapeutic targets that can significantly impact treatment decisions and patient outcomes. The articles in this section take a closer look at the current state of bladder cancer genetic testing, highlighting the clinical implications and potential future directions of precision oncology. A review article [5] by Professors Hyun Ho Han and Min Yong Kang on kidney cancer, Professor Seok Soo Byun on prostate cancer, and Professor Seok Jung Yoon on bladder cancer introduces genetic testing in urologic cancer. Localized or unresectable kidney cancer poses unique challenges for healthcare providers. Innovations in ablation and angioembolization have shown promising results as minimally invasive treatment options for these patients. Professor Eui-Chang Hwang [6] explains the Korean Society of Urological Oncology guidelines on angioembolization for kidney cancer. Professor Bumjin Lim [7] presents his excellent research in "Efficacy of Partial Nephrectomy in the Management of Unpredicted pT3a Renal Cell Carcinoma." The study of Lim [7] explores the effectiveness of partial nephrectomy as a potential treatment option.

In the bladder cancer session, Professor Jongjin Oh [8] discusses the evolving role of checkpoint inhibitors in treating urothelial cancer. Professor Wonsik Ham [9] will present a comparative analysis of radical cystectomy and bladder-sparing therapy in patients with muscle-invasive bladder cancer who have undergone nephroureterectomy. Professor Jungyo Suh [10] are focused on exploring the predictive value of preoperative systemic inflammatory response markers in identifying disease localized to the spleen in patients with upper tract urothelial carcinoma. This study strives to identify potential biomarkers to help in the early detection and risk stratification of aggressive forms of urothelial cancer.

As Editor-in-Chief of JUO, I would like to extend my sincere thanks to all the researchers, authors, and peer reviewers who made this issue possible. Their contributions have advanced our understanding of urologic cancer and paved the way for better patient care. We encourage readers to explore the diverse articles on this issue and believe that the insights presented here will inspire continued advances in the field of urologic oncology. Together, we can make a difference in the lives of patients affected by this challenging disease.